Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.20.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenues    
Royalty $ 240
Product sales 304
Total Revenues 544
Operating Expenses    
Research and development 3,894,966 2,474,559
General and administrative 1,703,522 1,229,440
Sales and marketing 273,954 284,280
Total Operating Expenses 5,872,442 3,988,279
Operating Loss (5,871,898) (3,988,279)
Other Income (Expenses)    
Grant income 7,924
Interest income 38,414 11,564
Interest expense (33,779) (30,101)
Other expenses (196,957)
Total Other Income (Expenses) 12,559 (215,494)
Provision for Income Taxes
Net Loss (5,859,339) (4,203,773)
Net Loss attributable to Non-Controlling Interest 9,567
Net Loss attributable to VolitionRx Limited Stockholders (5,849,772) (4,203,773)
Other Comprehensive Income (Loss)    
Foreign currency translation adjustments 373,926 (24,055)
Net Comprehensive Loss $ (5,485,413) $ (4,227,828)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited $ (0.14) $ (0.12)
Weighted Average Shares Outstanding    
Basic and Diluted 41,197,125 36,212,897